Japan's Takeda plans to sell consumer health unit for around $3.7 billion - Nikkei [Reuters]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Reuters
Japan's Takeda plans to sell consumer health unit for around $3.7 billion - Nikkei TOKYO (Reuters) - Japan’s Takeda Pharmaceutical Co Ltd plans to sell its consumer health unit for around 400 billion yen ($3.72 billion), Nikkei Business reported. Possible buyers of Takeda Consumer Healthcare Co include Taisho Pharmaceutical Co. and large investment funds, Nikkei reported. Spokespeople for both Takeda and Taisho declined to comment. Takeda Chief Executive Christophe Weber said last year that a sale of the Japan-focused consumer unit, known for its Alinamin line of energy drinks, was unlikely. Japan’s biggest pharma company would focus on overseas divestitures in its pledge to sell $10 billion of assets to reduce debt in the wake of the $59 billion purchase of Shire Plc, Weber said at the time. It completed $7 billion of divestments in calendar 2019, including assets in the Middle East and Africa and a dry-eye drug sold for $5.3 billion to Novartis, Refinitiv data show. Takeda is due to
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- American Neurology Summit 2025 Achieves Major Success With Full Attendance and High EngagementPR Web
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 12/5/25 - Form 144
- 12/4/25 - Form 144
- 11/28/25 - Form 6-K
- TAK's page on the SEC website